{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:24:33Z","timestamp":1789428273382,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers like malignant melanoma. However, they can lead to a range of immune-related adverse events (irAEs), impacting various organ systems. Among these, myositis is a rare but serious irAE, typically characterized by myalgia, muscle weakness, and elevated creatine kinase (CK) levels. Herein, we report the case of a 58-year-old female with advanced melanoma, who presented a delayed-onset of ICI-induced myositis accompanied by severe muscle weakness. Interestingly, the CK levels remained normal throughout her disease course. Neurological examination, MRI, and electromyography were pivotal in diagnosing myositis. Differential diagnoses, including myasthenia gravis, myocarditis, and paraneoplastic syndromes or idiopathic inflammatory myopathies, were systematically ruled out through clinical evaluation, serological testing, and imaging. The patient responded favorably to high-dose corticosteroid therapy, leading to a gradual improvement of symptoms and no relapse after stopping treatment. This case report emphasizes a multimodal diagnostic approach and underscores the importance of clinical awareness for such atypical irAE presentations.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1592385","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:26:42Z","timestamp":1750829202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase"],"prefix":"10.3389","volume":"16","author":[{"given":"Klajdi","family":"Begaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Lepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Kaufhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Veeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henner","family":"Stege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers16071440","article-title":"Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations","volume":"16","author":"Casagrande","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1292122","article-title":"Achilles\u2019 Heel of currently approved immune checkpoint inhibitors: immune related adverse events","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1634\/theoncologist.2016-0170","article-title":"A case of nivolumab-induced myositis","volume":"21","author":"Fox","year":"2016","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12134-x","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series","volume":"271","author":"Vicino","year":"2024","journal-title":"J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.884776","article-title":"Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature","volume":"13","author":"Nakagomi","year":"2022","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: A systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001874","article-title":"Immune checkpoint inhibitor-associated myositis: A distinct form of inflammatory myopathy","volume":"28","author":"Saygin","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223792","article-title":"Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/q7mdjs","article-title":"Immune checkpoint inhibitor-related myositis: from pathophysiology to treatment","volume":"41","author":"Sundarrajan","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.01.030","article-title":"Nivolumab-induced myositis: A case report and a literature review","volume":"387","author":"Bourgeois-Vionnet","year":"2018","journal-title":"J Neurol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0911","article-title":"Statin intolerance, anti-HMGCR antibodies, and immune checkpoint inhibitor-associated myositis: A \u201cTwo-hit\u201d Autoimmune toxicity or clinical predisposition","volume":"25","author":"von Itzstein","year":"2020","journal-title":"Oncologist"},{"key":"B22","article-title":"Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells","volume":"30","author":"Casciola-Rosen","year":"2012","journal-title":"Clin Exp Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1592385\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:26:43Z","timestamp":1750829203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1592385\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1592385"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1592385","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"article-number":"1592385"}}